Related Experiment Videos
Cardioprotection and antihypertensive therapy. Are beta-blockers the only effective therapy?
1Department of Medicine, James Connolly Hospital, Dublin, Ireland.
Insights
Hypertension management significantly reduces stroke and heart failure risks. While effective for established hypertension, its primary prevention of coronary artery disease remains challenging.
Area of Science:
- Cardiology
- Public Health
Background:
- Hypertension is a prevalent chronic condition, affecting a quarter of adults and increasing with age.
- It is a significant risk factor for stroke, coronary heart disease, morbidity, and mortality, especially when combined with factors like smoking.
Purpose of the Study:
- To assess the efficacy of antihypertensive therapy in controlling blood pressure.
- To evaluate the reduction of hypertension-associated morbidity and mortality.
- To determine the role of antihypertensive therapy in the primary prevention of coronary artery disease.
Main Methods:
- Analysis of numerous clinical trials involving over 40,000 subjects worldwide.
- Review of evidence from early trials like the Veterans Administration trial and subsequent studies.
Main Results:
- Antihypertensive therapy benefits are well-established, even for milder forms of hypertension, offering protection against malignant hypertension, heart failure, stroke, and renal failure.
- Therapy has been less successful in the primary prevention of coronary artery disease.
Conclusions:
- Beta-blockers and calcium channel blockers are recommended as first-line therapy for hypertension due to their efficacy and manageable side effect profiles compared to thiazide diuretics.
- Further research may explore the prophylactic use of beta-blockers for hypertension-related coronary disease.
Abstract:
Hypertension is a major risk factor for stroke and coronary heart disease and this increases with increasing age. It is a chronic disease which affects a quarter of the adult population. On its own or in conjunction with other risk factors, especially cigarette smoking, hypertension is associated with serious morbidity and high mortality. A large number of clinical trials have been undertaken to assess the efficacy of antihypertensive therapy in controlling high blood pressure and in reducing the morbidity and mortality associated with hypertension. These trials have studied more than 40,000 subjects worldwide as a result of which the benefits of treatment even in milder forms of hypertension are well established today. However, antihypertensive therapy has been disappointingly unsuccessful in the primary prevention of coronary artery disease despite the undoubted protection against malignant phase hypertension, heart failure, stroke and renal failure as demonstrated in the early Veterans Administration trial and subsequent studies. The success of post-infarction beta-blockade suggested that the wider use of beta-blockers prophylactically might limit hypertension-related coronary disease. Taking into account the adverse and metabolic effects of thiazide diuretics, beta-blockers together with calcium channel blockers must remain the drugs of choice as step one therapy in most patients with hypertension.